Auxo Firm Directory · Independent Research Profile

Linden Capital Partners

Linden Capital Partners is a healthcare private equity firm operating through Linden LLC. It targets companies with $10-$40+ million of EBITDA and primarily pursues leveraged buyouts or transactions in which it can be the lead investor or exercise significant governance influence.

Key takeaway

Linden focuses exclusively on healthcare and targets companies with $10-$40+ million of EBITDA.

Its stated approach combines buyout investing with active ownership, management collaboration, operating partners, advisors, and board oversight.[1][2][3][6]

What does Linden Capital Partners invest in?

Linden Capital Partners is a Chicago-based healthcare private equity firm founded in 2004 and operating through Linden LLC. Linden states that it primarily invests through leveraged buyouts or other transactions in which it can be the lead investor or have significant governance influence.

Linden’s official regulatory information page states that it is an investment adviser registered with the United States Securities and Exchange Commission under the Investment Advisers Act of 1940. Its official Our Firm page reports approximately $14 billion of regulatory assets under management as of December 31, 2025.[1][2][4]

Linden describes a Value Creation Program that extends from initial evaluation through transition. The program integrates sector-focused strategies, investment theses, operational priorities, management collaboration, operating partners, advisors, and board oversight.

Linden states that its Value Creation Program is based on financial and operating goals to be realized over a four-to-seven-year investment period. It also states that it primarily pursues leveraged buyouts or transactions involving lead-investor status or significant governance influence, rather than venture capital investments.[2]

Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.

EBITDAPublicly stated range
Lower published point$10
Upper published point$14BILLION

Published criteria: Linden states that it targets companies with $10-$40+ million of EBITDA. Its official Our Firm page reports approximately $14 billion of regulatory assets under management as of December 31, 2025.[2]

What should a business owner evaluate before considering a transaction with Linden Capital Partners?

An owner evaluating Linden should clarify the proposed governance structure, including whether Linden would seek a lead-investor role or significant governance influence and what governance influence would apply. Linden states that an ideal transaction may allow the current owner to retain a stake while participating in planned growth and value creation, so rollover structure, valuation, dilution, and related economics should be addressed directly.

The owner should also ask how the Value Creation Program, management collaboration, operating-partner involvement, board oversight, and four-to-seven-year investment-period framework would apply to the specific transaction. The cited Value Creation Program page does not publish universal fee, carried-interest, minimum equity-check, or standardized seller-specific pricing terms.[2]

01

What equity check size and leverage parameters would apply to this opportunity

The cited Value Creation Program page states an EBITDA target but does not publish a minimum equity check or standardized seller-specific pricing terms.[2]
02

Would Linden seek to be the lead investor or exercise significant governance influence, and what governance rights would the seller retain

Linden describes leveraged buyouts and other transactions in which it can be the lead investor or have significant governance influence.[2]
03

How would any seller rollover stake be sized, valued, and treated in future financings or acquisitions

Linden states that an ideal transaction may allow the current owner to retain a stake while participating in planned growth and value creation.[2]

What companies does Linden Capital Partners target?

Linden states that it targets companies with $10-$40+ million of EBITDA. Its stated transaction approach emphasizes leveraged buyouts and situations in which Linden can be the lead investor or have significant governance influence.[2]

Linden focuses on healthcare services, products, and distribution. Listed areas include behavioral health, dental service organizations, healthcare information technology, multi-site providers, payor services, pharmaceutical and pharmacy services, physician groups, post-acute care, contract manufacturing, dental products, devices, diagnostics, specialty pharmaceuticals, home health and non-acute distribution, hospital distribution, and specialty products.[3]

Linden is based in Chicago. The cited Industry Focus page lists healthcare sectors but does not state a formal geographic investment mandate or geographic exclusion policy.[1][3]

Linden describes transactions in which a current owner may retain a stake while participating in planned growth and value creation. The sources cited for this profile do not establish whether Linden uses a separately defined platform-and-add-on investment framework.[2]

Official Linden materials identify ArtesRx, Regenity Biosciences, Alcresta Therapeutics, StatLab Medical Products, and Specialty Networks among named portfolio or transaction companies. These examples include behavioral-health pharmacy, biosciences, gastrointestinal and rare-disease products, and medical products.[5][6][7][8][9]

  • On August 24, 2026, Linden announced a partnership with ArtesRx, a behavioral-health pharmacy platform serving patients with complex medication regimens.
  • On February 12, 2026, Cinven agreed to make a strategic investment in Regenity Biosciences, a Linden portfolio company, creating a partnership between Cinven and Linden.
  • On July 14, 2026, Linden and Audax Private Equity announced an agreement to sell StatLab Medical Products to Leica Biosystems, subject to customary closing conditions.
  • On March 12, 2024, Linden announced completion of its acquisition of Alcresta Therapeutics.
  • On January 31, 2024, Linden announced an agreement to sell Specialty Networks to Cardinal Health for $1.2 billion in cash.
[5][6][7][8][9]

What is not clear from Linden Capital Partners's public investment criteria?

The cited Industry Focus page does not state a formal geographic investment mandate or geographic exclusion policy. The cited Value Creation Program page does not publish a universal fee schedule, carried-interest schedule, minimum equity check, or standardized seller-specific pricing terms. The cited Regenity transaction announcement states that financial terms were not disclosed.[2][3][6]

Questions to ask when evaluating Linden Capital Partners as a buyer or investment partner

What equity check size and leverage parameters would apply to this opportunity?
The cited Value Creation Program page states an EBITDA target but does not publish a minimum equity check or standardized seller-specific pricing terms.[2]
Would Linden seek to be the lead investor or exercise significant governance influence, and what governance rights would the seller retain?
Linden describes leveraged buyouts and other transactions in which it can be the lead investor or have significant governance influence.[2]
How would any seller rollover stake be sized, valued, and treated in future financings or acquisitions?
Linden states that an ideal transaction may allow the current owner to retain a stake while participating in planned growth and value creation.[2]
Which elements of Linden's Value Creation Program would apply to the specific company?
Linden describes a program involving management collaboration, operating partners, advisors, operational priorities, and board oversight from evaluation through transition.[2]
How would the four-to-seven-year investment-period framework apply to this transaction?
Linden states that its Value Creation Program is based on financial and operating goals to be realized over a four-to-seven-year investment period.[2]
What transaction fees, monitoring fees, expense allocations, and other economic terms would apply?
The cited Value Creation Program page does not publish a universal fee schedule, carried-interest schedule, or standardized seller-specific pricing terms.[2]
What terms and conditions would apply if the transaction involved a future strategic investment or sale?
Linden’s public announcements include both strategic investment activity and agreements to sell portfolio companies, while the cited Regenity announcement states that financial terms were not disclosed.[6][7][9]

Sources & research notes

Public-source research
  1. Official website / firm overview
  2. Services / capabilities
  3. Industry / market focus
  4. Structure / regulatory context
  5. Transaction / portfolio evidence
  6. Transaction / portfolio evidence
  7. Transaction / portfolio evidence
  8. Transaction / portfolio evidence
  9. Transaction / portfolio evidence
Prepared and reviewed by: Auxo Capital AdvisorsEvidence standard: Public-source verification

How this profile was researched

Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.

Independent profile & regulatory context

Independent research profile

This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.

Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.

Broker-dealer and securities disclosure

Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.

Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.

Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.

Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.